Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic β-cells

Islets

Volumn 5, Issue 2, 2013, Pages 95-105

  Russell, Mark A ^a   Cooper, Angela C ^b   Dhayal, Shalinee ^a   Morgan, Noel G ^a  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

Interleukin 13; Interleukin 6; Janus kinase; Pancreatic cells; STAT3; STAT6

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 6; JANUS KINASE; STAT3 PROTEIN; STAT6 PROTEIN;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; INTRACELLULAR SIGNALING; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING;

EID: 84879335777     PISSN: 19382014     EISSN: 19382022     Source Type: Journal    
DOI: 10.4161/isl.24249     Document Type: Article

References (49)

1. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39:1005-29; PMID:8877284; http://dx.doi.org/10.1007/ BF00400649 (Pubitemid 26275930)
2. Eizirik DL, Mandrup-Poulsen T. A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44:2115-33; PMID:11793013; http://dx.doi.org/10.1007/s001250100021 (Pubitemid 34015464)
3. Rapoport MJ, Mor A, Vardi P, Ramot Y, Winker R, Hindi A, et al. Decreased secretion of Th2 cytokines precedes Up-regulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. J Autoimmun 1998; 11:635-42; PMID:9878085; http://dx.doi.org/10.1006/jaut.1998.0240 (Pubitemid 29016121)
4. Berman MA, Sandborg CI, Wang Z, Imfeld KL, Zaldivar F Jr., Dadufalza V, et al. Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus. J Immunol 1996; 157:4690-6; PMID:8906850 (Pubitemid 126449393)
5. Marselli L, Dotta F, Piro S, Santangelo C, Masini M, Lupi R, et al. Th2 cytokines have a partial, direct protective effect on the function and survival of isolated human islets exposed to combined proinflammatory and Th1 cytokines. J Clin Endocrinol Metab 2001; 86:4974-8; PMID:11600573; http://dx.doi.org/10. 1210/jc.86.10.4974 (Pubitemid 33020552)
6. Kaminski A, Kaminski ER, Morgan NG. Preincubation with interleukin-4 mediates a direct protective effect against the loss of pancreatic beta-cell viability induced by proinflammatory cytokines. Clin Exp Immunol 2007; 148:583-8; PMID:17403060; http://dx.doi.org/10.1111/j.1365-2249.2007.03375.x (Pubitemid 46701038)
7. Souza KL, Gurgul-Convey E, Elsner M, Lenzen S. Interaction between pro-inflammatory and anti-inflammatory cytokines in insulin-producing cells. J Endocrinol 2008; 197:139-50; PMID:18372240; http://dx.doi.org/10.1677/JOE-07- 0638 (Pubitemid 351566933)
8. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41:1241-8; PMID:9794114; http://dx.doi.org/ 10.1007/s001250051058 (Pubitemid 28449093)
9. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11:98-107; PMID:21233852; http://dx.doi.org/10.1038/nri2925
10. Campbell IL, Cutri A, Wilson A, Harrison LC. Evidence for IL-6 production by and effects on the pancreatic beta-cell. J Immunol 1989; 143:1188-91; PMID:2501390 (Pubitemid 19211345)
11. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 2010; 21:261-7; PMID:20096598; http://dx.doi.org/10.1016/j.tem.2009.12.010
12. Olsson A, Johansson U, Korsgren O, Frisk G. Inflammatory gene expression in Coxsackievirus B-4-infected human islets of Langerhans. Biochem Biophys Res Commun 2005; 330:571-6; PMID:15796921; http://dx.doi.org/10.1016/j.bbrc.2005.03. 016 (Pubitemid 40417683)
13. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 2009; 52:1143-51; PMID:19266182; http://dx.doi.org/10.1007/s00125-009-1276-0
14. Richardson SJ, Willcox A, Bone AJ, Morgan NG, Foulis AK. Immunopathology of the human pancreas in type-I diabetes. Semin Immunopathol 2011; 33:9-21; PMID:20424842; http://dx.doi.org/10.1007/s00281-010-0205-0
15. Roy B, Bhattacharjee A, Xu B, Ford D, Maizel AL, Cathcart MK. IL-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats. J Leukoc Biol 2002; 72:580-9; PMID:12223527
16. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 1999; 93:1980-91; PMID:10068671 (Pubitemid 29128500)
17. Kaminski A, Welters HJ, Kaminski ER, Morgan NG. Human and rodent pancreatic beta-cells express IL-4 receptors and IL-4 protects against beta-cell apoptosis by activation of the PI3K and JAK/STAT pathways. Biosci Rep 2010; 30:169-75; PMID:19531027; http://dx.doi.org/10.1042/BSR20090021
18. Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 2002; 8:240-6; PMID:11875494; http://dx.doi.org/10.1038/nm0302-240 (Pubitemid 34250101)
19. Ellingsgaard H, Ehses JA, Hammar EB, Van Lommel L, Quintens R, Martens G, et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 2008; 105:13163-8; PMID:18719127; http://dx.doi.org/10.1073/pnas. 0801059105
20. Villanueva EC, Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Int J Obes (Lond) 2008; 32(Suppl 7):S8-12; PMID:19136996; http://dx.doi.org/10.1038/ijo.2008.232
21. Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner KU, et al. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Mol Endocrinol 2007; 21:2218-32; PMID:17550976; http://dx.doi.org/10.1210/me. 2007-0173 (Pubitemid 47347383)
22. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003; 300:1527-8; PMID:12791978; http://dx.doi.org/10.1126/science.1085458 (Pubitemid 36686713)
23. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003; 111:677-90, quiz 691; PMID:12704343; http://dx.doi.org/10.1067/mai.2003.1333 (Pubitemid 36470232)
24. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374:1-20; PMID:12773095; http://dx.doi.org/10.1042/ BJ20030407 (Pubitemid 37046923)
25. Andrews R P, Ericksen MB, Cunningham CM, Daines MO, Hershey GK. Analysis of the life cycle of stat6. Continuous cycling of STAT6 is required for IL-4 signaling. J Biol Chem 2002; 277:36563-9; PMID:12121972; http://dx.doi.org/10. 1074/jbc.M200986200
26. Carey GB, Semenova E, Qi X, Keegan AD. IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contribution of the PI-3 kinase/AKT pathway. Cell Res 2007; 17:942-55; PMID:17968425; http://dx.doi.org/10.1038/sj.cr.2007.90 (Pubitemid 350126865)
27. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, et al. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 2003; 305:462-9; PMID:12763015; http://dx.doi.org/10.1016/ S0006-291X(03)00792-7 (Pubitemid 36579252)
28. Lust JA, Donovan KA, Kline M P, Greipp PR, Kyle RA, Maihle NJ. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 1992; 4:96-100; PMID:1633265; http://dx.doi.org/10.1016/1043-4666(92)90043-Q
29. Nishimura Y, Nitto T, Inoue T, Node K. IL-13 attenuates vascular tube formation via JAK2-STAT6 pathway. Circ J 2008; 72:469-75; PMID:18296848; http://dx.doi.org/10.1253/circj.72.469 (Pubitemid 351600645)
30. Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 2006; 66:9714-21; PMID:17018630; http://dx.doi.org/10.1158/0008-5472.CAN-05-4280 (Pubitemid 44623672)
31. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24:325-31; PMID:19996363; http://dx.doi.org/10.1152/physiol. 00032.2009
32. Zaccone P, Phillips J, Conget I, Gomis R, Haskins K, Minty A, et al. Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes 1999; 48:1522-8; PMID:10426368; http://dx.doi.org/10.2337/diabetes.48.8.1522 (Pubitemid 29356858)
33. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71:169-75; PMID:8181185; http://dx.doi.org/10.1006/clin.1994.1068 (Pubitemid 24147233)
34. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178:87-99; PMID:8315397; http://dx.doi.org/10.1084/jem.178.1.87 (Pubitemid 23173245)
35. Gaddy D F, Riedel MJ, Bertera S, Kieffer TJ, Robbins PD. dsAAV8-mediated gene transfer and β-cell expression of IL-4 and β-cell growth factors are capable of reversing early-onset diabetes in NOD mice. Gene Ther 2011; 19:791-9; PMID:22089495; http://dx.doi.org/10.1038/gt.2011.181
36. Rehman KK, Trucco M, Wang Z, Xiao X, Robbins PD. AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice. Mol Ther 2008; 16:1409-16; PMID:18560422; http://dx.doi.org/10.1038/mt.2008.116
37. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813:878-88; PMID:21296109; http://dx.doi.org/10.1016/j.bbamcr.2011.01. 034
38. Drucker C, Gewiese J, Malchow S, Scheller J, RoseJohn S. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. J Autoimmun 2010; 34:29-37; PMID:19717281; http://dx.doi.org/10.1016/j.jaut.2009. 08.003
39. Doganci A, Eigenbrod T, Krug N, De Sanctis G T, Hausding M, Erpenbeck VJ, et al. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest 2005; 115:313-25; PMID:1566874. (Pubitemid 40385473)
40. Hebenstreit D, Wirnsberger G, Horejs-Hoeck J, Duschl A. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev 2006; 17:173-88; PMID:16540365; http://dx.doi.org/10.1016/j.cytogfr. 2006.01.004 (Pubitemid 43816893)
41. Wadt KA, Larsen CM, Andersen HU, Nielsen K, Karlsen AE, Mandrup-Poulsen T. Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1beta in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. Diabetes 1998; 47:1602-8; PMID:9753298; http://dx.doi.org/10.2337/diabetes.47.10.1602 (Pubitemid 28445348)
42. Oh YS, Lee YJ, Park EY, Jun HS. Interleukin-6 treatment induces beta-cell apoptosis via STAT-3-mediated nitric oxide production. Diabetes Metab Res Rev 2011; 27:813-9; PMID:22069265; http://dx.doi.org/10.1002/dmrr.1233
43. Kolios G, Wright KL, Linehan JD, Robertson DA, Westwick J. Interleukin-13 inhibits nitric oxide production in human colonic mucosa. Hepatogastroenterology 2000; 47:714-7; PMID:10919016 (Pubitemid 30417279)
44. Bogdan C, Thüring H, Dlaska M, Röllinghoff M, Weiss G. Mechanism of suppression of macrophage nitric oxide release by IL-13: influence of the macrophage population. J Immunol 1997; 159:4506-13; PMID:9379051 (Pubitemid 127470612)
45. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 1992; 130:167-78; PMID:1370150; http://dx.doi.org/10.1210/en.130. 1.167
46. McCluskey JT, Hamid M, Guo-Parke H, McClenaghan NH, Gomis R, Flatt PR. Development and functional characterization of insulin-releasing human pancreatic beta cell lines produced by electrofusion. J Biol Chem 2011; 286:21982-92; PMID:21515691; http://dx.doi.org/10.1074/jbc.M111.226795
47. Kissler HJ, Niland JC, Olack B, Ricordi C, Hering BJ, Naji A, et al. Validation of methodologies for quantifying isolated human islets: an Islet Cell Resources study. Clin Transplant 2010; 24:236-42; PMID:19719726; http://dx.doi.org/10.1111/j.1399-0012.2009.01052.x
48. Morgan NG, Diakogiannaki E, Russell MA. The incubation and monitoring of cell viability in primary rat islets of Langerhans and pancreatic beta-cell lines. Methods Mol Biol 2009; 560:53-64; PMID:19504243; http://dx.doi.org/10. 1007/978-1-59745-448-3-5
49. Welters HJ, Oknianska A, Erdmann KS, Ryffel GU, Morgan NG. The protein tyrosine phosphatase-BL, modulates pancreatic beta-cell proliferation by interaction with the Wnt signalling pathway. J Endocrinol 2008; 197:543-52; PMID:18413347; http://dx.doi.org/10.1677/JOE-07-0262 (Pubitemid 351803958)